All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis
Authors:
- Takashi OguraTOTakashi Ogura
- Arata AzumaAAArata Azuma
- Yoshikazu InoueYIYoshikazu Inoue
- Hiroyuki TaniguchiHTHiroyuki Taniguchi
- Kingo ChidaKCKingo Chida
- Masashi BandoMBMasashi Bando
- Yuka NiimiYNYuka Niimi
- Shinichi KakutaniSKShinichi Kakutani
- Moritaka SugaMSMoritaka Suga
- Yukihiko SugiyamaYSYukihiko Sugiyama
- Shoji KudohSKShoji Kudoh
- Toshihiro NukiwaTNToshihiro Nukiwa
- 1 September 2015
- journal article
- research article
- Published by Elsevier in Respiratory Investigation
- Vol. 53 (5) , 232-241
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effects of pirfenidone on increased cough reflex sensitivity in guinea pigsPulmonary Pharmacology & Therapeutics, 2013
- Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practiceRespiratory Medicine, 2013
- The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trialRespiratory Research, 2011
- Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatmentRespiratory Research, 2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pirfenidone in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA DatasetsJournal of Biopharmaceutical Statistics, 2009
- Open-label Compassionate Use One Year-treatment with Pirfenidone to Patients with Chronic Pulmonary Fibrosis.Internal Medicine, 2002